.jpeg)
{{ variable.name }}
Trelagliptin is a long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Takeda of Japan.
1. Common name : Trelagliptin succinate (Trelag liptinSuccinate)
2. Product name :Zafatek®(ザファテック町)
< b>3. Dosage form :Film-coated tablets
4. Main ingredients :Each tablet contains trotagliptin succinate 133mg (equivalent to trotagliptin 100mg), 66.5mg (50mg) or 33.25mg (25mg). Excipients include D-mannitol, microcrystalline cellulose, croscarmellose sodium, etc.
Type 2 diabetes : Suitable for adult patients who are poorly controlled by diet and exercise therapy and need to be combined with basic treatment.
1. Specifications of : 100mg (light red diamond-shaped tablets), 50mg (light yellow-red diamond-shaped tablets).
2. Characteristics : The long diameter of 100mg tablets is 11.0mm, and the long diameter of 50mg tablets is 8.2mm, both of which are printed with dosage labels.
1. Recommended dose : 100mg once a week, orally at a fixed time.
2. Dietary requirements : It is recommended to take it 30 minutes before breakfast.
3. Treatment of missed doses : Immediately take a missed dose after discovering it, and then resume the original medication cycle.
1. Renal insufficiency : Reduce to 50mg/week for moderate (Ccr30-50mL/min), and reduce to 25mg/week for severe (Ccr<30mL/min) or dialysis patients.
2. Liver insufficiency : No adjustment is required for mild to moderate, and it is disabled for severe cases.
1. Risk of hypoglycemia : Blood sugar needs to be monitored when combined with sulfonylureas or insulin.
2. Pancreatitis : If persistent abdominal pain and vomiting occur, the medication must be stopped immediately.
3. Intestinal obstruction : Use with caution in those with a history of abdominal surgery.
4. PTP packaging : It is necessary to take out the tablets to avoid accidentally swallowing the aluminum foil.
1. Pregnant women: : Disabled (animal experiments show fetal toxicity).
2. During lactation : Discontinue medication or stop breastfeeding.
3. Children : Safety has not been established.
4. Elderly : The dosage needs to be adjusted according to renal function.
1. Common (≥1%) : Hypoglycemia (0.4-7.8%), nasopharyngitis (3.2%), constipation (1.6%).
2. Severe reactions : Acute pancreatitis (unknown frequency), intestinal obstruction (unknown frequency).
1. Type 1 diabetes or diabetic ketoacidosis;
2. Severe infection, trauma or during surgery;
3. Those allergic to ingredients.
1. Strong CYP3A4 inhibitor (such as ketoconazole): combination is prohibited;
2. Sulfonylureas/insulin : increase the risk of hypoglycemia;
3. β-blocker : may mask the symptoms of hypoglycemia.
Store unopened medicines at room temperature (below 25°C) and avoid moisture and light.
Takeda Pharmaceutical Co., Ltd.
Note : Blood glucose and renal function need to be monitored regularly during treatment. Smoking may affect the efficacy, so it is recommended to quit smoking.